Allergic reactions after messenger RNA (mRNA) COVID-19 vaccines have been reported to be as high as 2%, with anaphylaxis occurring in up to 2.5 per 10 000 individuals. 1 There is uncertainty as to whether to administer a second dose of mRNA COVID-19 vaccine after a firstdose reaction. 2,3 In this study, we examine the safety of the second dose of Pfizer-BioNTech or Moderna vaccine in those with a history of immediate and potentially allergic reactions to the first dose.Methods | This multicenter, retrospective study conducted by Massachusetts General Hospital (Boston), Brigham and Women's Hospital (Boston, Massachusetts),

No abstract

In conclusion, current evidence suggests that colchicine therapy is efficacious for the prevention of post-operative AF, and may be considered as adjunctive prophylaxis. Further studies may be required to determine the optimal treatment protocol to reduce the incidence of gastrointestinal intolerance.

Key PointsQuestionWhat is the risk of serious infections, opportunistic infections, and cancer in patients with rheumatologic diseases treated with interleukin inhibitors?FindingsIn this systematic review and meta-analysis of 74 randomized clinical trials comprising 29 214 patients, pooled results suggest that risk of serious infections, opportunistic infections, and cancer is increased in patients with rheumatologic diseases who are treated with interleukin inhibitors compared with placebo.MeaningThis analysis suggests estimates of risk for infections and cancer associated with the use of interleukin inhibitors that can inform shared decision-making when patients and clinicians are contemplating the use of interleukin inhibitors for rheumatologic diseases.

We report our case series involving the use of a MicroOptical (MicroOptical Corporation, Westwood, MA, USA) head mounted, computer display monitor during orthopaedic procedures such as open reduction and internal fracture fixations and spinal pedicle screw placement. Since the MicroOptical viewer does not fully obstruct the surgeon's direct vision, he/she may continue to operate and focus on the operative field while viewing the MicroOptical image. Our first 50 clinical applications demonstrate that when viewing the MicroOptical monitor there is a significant reduction in the total number of times the surgeon left the attention of the operative field and/or may have been exposed to fluoroscopy radiation by unprotected body turn exposure. In addition, the MicroOptical viewer did not cause any surgical field viewing obstruction during surgical procedures and there was not a difference in reported surgeon eye fatigue when comparing the MicroOptical viewer to standard fluoroscopy.